Osteogenesis imperfecta

Zusammenfassung

Osteogenesis imperfecta (OI) ist eine erbliche Erkrankung, die durch eine erniedrigte Knochenmasse und erhöhte Knochenbrüchigkeit charakterisiert ist. OI ist durch ein breites phänotypisches Spektrum gekennzeichnet, das traditionell durch die Klassifikation in vier verschiedene OI-Typen (OI Typ I–IV) abgebildet wird. Diese Klassifikation wurde zuletzt auf der Grundlage weiterer klinischer Kriterien um drei OI-Typen erweitert (OI Typ V–VII). Die Kenntnis histologischer Besonderheiten, neuer autosomal-rezessiver Formen und genetischer Mutationen kann wesentlich zur korrekten Diagnose und Behandlung eines Patien-ten mit OI beitragen. Dieser Review beschreibt neben der Klassifikation und dem klinischen Bild auch neue pathophysiologische Besonderheiten dieser Erkrankung. Der gegenwärtige Stand der medikamentösen Therapie wird ausführlich diskutiert.

Summary

Osteogenesis imperfecta (OI) is a heritable disorder characterized by low bone mass and increased bone fragility. OI presents with a broad clinical spectrum that is traditionally described by a classification combining four different types of disease severity (OI type I–IV). Recently, this classification was extended (OI type V–VII) on the basis of additional clinical features. The awareness of the histological picture and new autosomal recessive forms as well as the underlying genetic mutations helps to correctly diagnose and manage the OI patient. This review gives an update on the classification and clinical picture of OI and describes new pathopysiological mechanisms of the disease. Current concepts of medical treatment are comprehensively discussed.

Schlüsselwörter

Kinder - Osteogenesis imperfecta - Frakturen - Bisphosphonate

Keywords

Children - osteogenesis imperfecta - fractures - bisphosphonates

• Literatur

• 1 Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363: 1377-1385.
• 2 Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta--clinical and molecular diversity. Eur Cell Mater 2003; 05: 41-47. discussion 47.
• 3 Rauch F, Plotkin H, Zeitlin L, Glorieux FH. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003; 18: 610-614.
• 4 Rauch F, Land C, Cornibert S. et al. High and low density in the same bone: a study on children and adolescents with mild osteogenesis imperfecta. Bone 2005; 37: 634-641.
• 5 Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16: 101-116.
• 6 Glorieux FH, Rauch F, Plotkin H. et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650-1658.
• 7 Land C, Rauch F, Travers R, Glorieux FH. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment. Bone 2007; 40: 638-644.
• 8 Glorieux FH, Ward LM, Rauch F. et al. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res 2002; 17: 30-38.
• 9 Ward LM, Rauch F, Travers R. et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone 2002; 31: 12-18.
• 10 Labuda M, Morissette J, Ward LM. et al. Osteogenesis imperfecta type VII maps to the short arm of chromosome 3. Bone 2002; 31: 19-25.
• 11 Morello R, Bertin TK, Chen Y. et al. CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta. Cell 2006; 127: 291-304.
• 12 Cabral WA, Chang W, Barnes AM. et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal/severe osteogenesis imperfecta. Nat Genet 2007; 39: 359-365.
• 13 Prockop DJ, Colige A, Helminen H. et al. Mutations in type 1 procollagen that cause osteogenesis imperfecta: effects of the mutations on the assembly of collagen into fibrils, the basis of phenotypic variations, and potential antisense therapies. J Bone Miner Res 1993; 08 (Suppl. 02) S489-S492.
• 14 Byers PH. Osteogenesis imperfecta: perspectives and opportunities. Curr Opin Pediatr 2000; 12: 603-609.
• 15 Mundlos S, Chan D, Weng YM. et al. Multiexon deletions in the type I collagen COL1A2 gene in osteogenesis imperfecta type IB. Molecules containing the shortened alpha2(I) chains show differential incorporation into the bone and skin extracellular matrix. J Biol Chem 1996; 271: 21068-2174.
• 16 Grabner B, Landis WJ, Roschger P. et al. Age- and genotype-dependence of bone material properties in the osteogenesis imperfecta murine model (oim). Bone 2001; 29: 453-457.
• 17 Semler O, Fricke O, Vezyroglou K. et al. Preliminary results on the mobility after whole body vibration in immobilized children and adolescents. J Musculoskelet Neuronal Interact 2007; 07: 77-81.
• 18 Semler O, Fricke O, Vezyroglou K. et al. Results of a prospective pilot trial on mobility after whole body vibration in children and adolescents with osteogenesis imperfecta. Clin Rehabil 2008; 22: 387-394.
• 19 Ward L, Tricco A, Phuong P. et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev CD005324 2007;
• 20 Glorieux FH, Bishop NJ, Plotkin H. et al. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998; 339: 947-952.
• 21 Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002; 86: 356-364.
• 22 Zacharin M, Bateman J. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002; 15: 163-174.
• 23 Gatti D, Antoniazzi F, Prizzi R. et al. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study. J Bone Miner Res 2005; 20: 758-763.
• 24 Rauch F, Travers R, Plotkin H, Glorieux FH. The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002; 110: 1293-1299.
• 25 Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2006; 91: 511-516.
• 26 Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20: 1235-1243.
• 27 Land C, Rauch F, Munns CF. et al. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment. Bone 2006; 39: 901-906.
• 28 Letocha AD, Cintas HL, Troendle JF. et al. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 2005; 20: 977-986.
• 29 Montpetit K, Plotkin H, Rauch F. et al. Rapid Increase in Grip Force after Start of Pamidronate Therapy in Children and Adolescents and Severe Osteogenesis Imperfecta. Pediatrics 2003; 111: e106-e111.
• 30 Land C, Rauch F, Montpetit K. et al. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006; 148: 456-460.
• 31 Plotkin H, Rauch F, Bishop NJ. et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85: 1846-1850.
• 32 DiMeglio LA, Ford L, McClintock C, Peacock M. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004; 35: 1038-1045.
• 33 Glorieux FH, Bishop N, Bober M. et al. Intravenous zoledronic acid compared to iv pamidronate in children with severe osteogenesis imperfecta. 35th European Symposium on Calcified Tissues; Barcelona: 2008: Su-P067.
• 34 Rauch F, Plotkin H, Travers R. et al. Osteogenesis imperfecta types I,III and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003; 88: 986-992.
• 35 Khan AA, Sandor GK, Dore E. et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36: 478-490.
• 36 Malmgren B, Astrom E, Soderhal lS. No oste onecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 2008; 37: 196-200.
• 37 Chahine C, Cheung MS, Head TW. et al. Tooth extraction socket healing in pediatric patients treated with intravenous pamidronate. J Pediatr 2008; 153: 719-720.
• 38 Munns CF, Rauch F, Mier RJ, Glorieux FH. Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004; 35: 231-234.
• 39 Zeitlin L, Rauch F, Plotkin H, Glorieux FH. Height and weight development during long-term therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III and IV. Pediatrics 2003; 111: 1030-1036.
• 40 Munns CF, Rauch F, Zeitlin L. et al. Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004; 19: 1779-1786.
• 41 Land C, Rauch F, Glorieux FH. Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 374-379.
• 42 Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004; 19: 1742-1745.
• 43 Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91: 2017-2020.
• 44 Rauch F, Munns CF, Land C. et al. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 2009; 24: 1282-1289.
• 45 Sakkers R, Kok D, Engelbert R. et al. Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 2004; 363: 1427-1431.
• 46 Glorieux FH, Rauch F, Ward LM. et al. Alendronate in the treatment of pediatric osteogenesis imperfecta. Journal of Bone and Mineral Research 2004; 19: 12.
• 47 DiMeglio LA, Peacock M. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 2006; 21: 132-140.
• 48 Rauch F, Munns C, Land C, Glorieux FH. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006; 91: 1268-1274.